

PROVIDER Update



CONTRACTUAL | JULY 29, 2024 | UPDATE 24-799 | 4 PAGES

Medical Medication PA Updates and New Requirements

Learn about prior authorization (PA) changes in this update

The following pages have PA changes for commercial (HMO/POS, PPO), Ambetter HMO/PPO and Medi-Cal fee-for-service physicians and other providers.

AMA and CMS New Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS)

The below medical benefit medications and proprietary laboratory analyses (PLA) services require PA per new CPT and HCPCS codes issued by the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS).

Effective July 1, 2024

Code	Description	Brand/reference
J1748	Injection, infliximab-dyyb (Zymfentra), 10 mg	Self-Injectable: Zymfentra
J2267	Injection, mirikizumab-mrkz, 1 mg	Omvoh™
J3247	Injection, secukinumab, IV, 1 mg	Cosentyx®
J3393	Injection, betibeglogene autotemcel, per treatment	Loqtorzi™
J3394	Injection, lovetibeglogene autotemcel, per treatment	Zynteglo™
J7171	Injection, ADAMTS13, recombinant-krhn, 10 IU	Lyfgenia™
J7355	Injection, travoprost, intracameral implant, 1 mcg	Adzynma™
J9361	Injection, efbemalenograstim alfa-vuxw, 0.5 mg	iDose® TR (implant)

THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Community Support (CS) Providers
- Enhanced Care Management (ECM) Providers
- Behavioral Health Providers

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer/Group
 - HMO/POS
 - PPO
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP
Ambetter HMO – 888-926-2164

Ambetter from Health Net IFP
Ambetter PPO – 844-463-8188

Health Net Employer Group
HMO, POS & PPO – 800-641-7761

Medi-Cal (including CS and ECM providers)
– 800-675-6110
Behavioral Health providers –
844-966-0298

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

New HCPCS Codes, continued

Effective July 1, 2024

Code	Description	Brand/reference
Q5137	Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg	Ryzneuta™
Q5138	Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mg	Self-injectable: Wezlana™

New CPT Codes

Effective July 1, 2024

CPT Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Code	Description
0457U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative.
0459U	B-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology.
0462U	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary.
0468U	Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis.
0472U	Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiquantitative, blood, reported as predictive evidence of early Sjogren syndrome.

PA changes and deletions

View the tables below for PA requirements changes for Health Net* commercial HMO/POS, PPO and Medi-Cal physicians and other providers.

Medi-Cal

The below PA requirement changes are for Health Net's Medi-Cal fee-for-service physicians and other providers.

Medical Services and Outpatient Pharmaceuticals (Submitted under Medical Benefit)

Change

The following requires PA.

Benefit	Authorization required
Dental anesthesia	<ul style="list-style-type: none">• CPT 00170 – anesthesia on mouth for Current Dental Terminology procedures.• CPT 00190 – anesthesia for procedures on the head.• Reference prior communication – Find Out What Changed: Sedation and Anesthesia Coverage for Dental Services for Health Net, 24-109m at providerlibrary.healthnetcalifornia.com/news/24-109m-Find-Out-What-Changed-Sedation-and-Anesthesia-Coverage-for-Dental-Services.html.

Deletions, effective immediately

The following no longer require PA.

Benefit	Change
Adulhelm™	J0172, injection, aducanumab-avwa, 2 mg. Product discontinued.
Retacrit™	No longer requires PA when administered/provided under the medical benefit. ¹ <ul style="list-style-type: none">• Q5105 Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units.• Q5106 Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for non-ESRD use), 1000 units.
Zarxio®	No longer requires PA when administered/provided under the medical benefit. ¹ <ul style="list-style-type: none">• Q5101, Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg.
Sobering Centers	Update to the Authorization Guidelines for Sobering Centers – go to bit.ly/CalAIM_Resources . Select <i>Forms & Tools > Community Supports</i> , scroll down to Authorization Guides and click on Sobering Centers under <i>Health Net</i> .

¹PA is required when administered/provided under the pharmacy benefit.

Clinical trials

To receive urgent status for routine services requiring authorization that are related to a clinical trial, please either include the attestation form in your prior authorization request or indicate 'Routine Care Cost Services Associated with the Clinical Trial.' The state attestation form for clinical trials can be downloaded from bit.ly/Attest-Clinical_Trial.

For more information about [clinical trials](#), go to the Provider Library and select *Medi-Cal > Provider Manual > Benefits > Clinical Trials > Routine Care Costs for Qualifying Clinical Trials*.

Commercial and Ambetter

The below PA requirement changes are for Health Net's Commercial and Ambetter physicians and other providers.

Medical Services and Outpatient Pharmaceuticals (Submitted under Medical Benefit)

Addition, effective October 1, 2024

The following HCPCS requires PA for HMO/POS and PPO plans. Submit requests to eviCore at: www.evicore.com/ or fax to: 800-540-2406.

Benefit	Authorization required
Radiation therapy	HCPCS codes: <ul style="list-style-type: none">• A9609, fludeoxyglucose f18 up to 15 millicuries.• C9795, Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions.

Deletion, effective immediately

The following no longer require PA.

Benefit	Change
Adulhelm™	J0172, injection, aducanumab-avwa, 2 mg. Product discontinued.
Retacrit™	No longer requires PA when administered/provided under the medical benefit. ¹ <ul style="list-style-type: none">• Q5105 Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units.• Q5106 Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for non-ESRD use), 1000 units.
Zarxio®	No longer requires PA when administered/provided under the medical benefit. ¹ <ul style="list-style-type: none">• Q5101, Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg.
Sobering Centers	Update to the Authorization Guidelines for Sobering Centers – go to bit.ly/CalAIM_Resources . Select <i>Forms & Tools > Community Supports</i> , scroll down to Authorization Guides and click on Sobering Centers under <i>Health Net</i> .

¹PA is required when administered/provided under the pharmacy benefit.

Additional information

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center at provider_services@healthnet.com, by phone or through the Health Net provider portal as listed in the right-hand column on page 1. Behavioral health providers can call 844-966-0298.